Takashi Okada
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Takashi Okada has a total of 80 co-authors. Here are the top co-authors by number of shared publications:
Hironori Okada
8 shared publications- Shin-Ichi Takeda
Department of Surgery, Toneyama National Hospital
7 shared publications Tomoko Chiyo
7 shared publicationsYuko Nitahara-Kasahara
7 shared publicationsHiroaki Mizukami
Division of Genetic Therapeutics, Jichi Medical University, Tochigi, Japan
5 shared publicationsAkihiro Kume
Division of Genetic Therapeutics, Jichi Medical University, Tochigi, Japan
4 shared publications
Latest Publications
- Open Access
- 1 May 2016
- Published by Elsevier in Molecular Therapy
- Vol. 24, S134
337. Transient Ultrasound-Mediated Microbubble-Assisted Modulation of Blood-Brain Interface in Adult Common Marmoset to Improve rAAV-Mediated Brain Transduction
- 1 May 2016
- Published by Elsevier in Molecular Therapy
- Vol. 24, S134
Open Access337. Transient Ultrasound-Mediated Microbubble-Assisted Modulation of Blood-Brain Interface in Adult Common Marmoset to Improve rAAV-Mediated Brain Transduction
- Open Access
- 1 May 2016
- Published by Elsevier in Molecular Therapy
- Vol. 24, S93
238. Cell Therapeutic Approach Using Dental Pulp Stromal Cells for Duchenne Muscular Dystrophy
- 1 May 2016
- Published by Elsevier in Molecular Therapy
- Vol. 24, S93
Open Access238. Cell Therapeutic Approach Using Dental Pulp Stromal Cells for Duchenne Muscular Dystrophy
- Open Access
- 1 May 2016
- Published by Elsevier in Molecular Therapy
- Vol. 24, S150-S151
378. Improved Transduction of Canine X-Linked Muscular Dystrophy with rAAV9-Microdystrophin by Introducing Immune Tolerance
- 1 May 2016
- Published by Elsevier in Molecular Therapy
- Vol. 24, S150-S151
Open Access378. Improved Transduction of Canine X-Linked Muscular Dystrophy with rAAV9-Microdystrophin by Introducing Immune Tolerance
- Open Access
- 1 May 2015
- Published by Elsevier in Molecular Therapy
- Vol. 23, S142
357. Blood-Brain Interface Opening By Ultrasound in Adult Common Marmoset To Induce Brain Pathology With rAAV
- 1 May 2015
- Published by Elsevier in Molecular Therapy
- Vol. 23, S142
Open Access357. Blood-Brain Interface Opening By Ultrasound in Adult Common Marmoset To Induce Brain Pathology With rAAV
- Open Access
- 1 May 2015
- Published by Elsevier in Molecular Therapy
- Vol. 23, S159
402. Mesenchymal Stromal Cells Can Ameliorate the Progressive Phenotype of Dog With Duchenne Muscular Dystrophy
- 1 May 2015
- Published by Elsevier in Molecular Therapy
- Vol. 23, S159
Open Access402. Mesenchymal Stromal Cells Can Ameliorate the Progressive Phenotype of Dog With Duchenne Muscular Dystrophy
- Open Access
- 1 May 2015
- Published by Elsevier in Molecular Therapy
- Vol. 23, S158-S159
400. Improved Transduction of Canine X-Linked Muscular Dystrophy With rAAV9-Microdystrophin By Using MSCs Pretreatment
- 1 May 2015
- Published by Elsevier in Molecular Therapy
- Vol. 23, S158-S159
Open Access400. Improved Transduction of Canine X-Linked Muscular Dystrophy With rAAV9-Microdystrophin By Using MSCs Pretreatment
- Open Access
- 27 June 2013
- Published by MDPI AG in Pharmaceuticals
- Vol. 6 (7) , 813-836
Current Challenges and Future Directions in Recombinant AAV-Mediated Gene Therapy of Duchenne Muscular Dystrophy
Various characteristics of adeno-associated virus (AAV)-based vectors with long-term safe expression have made it an exciting transduction tool for clinical gene therapy of Duchenne muscular dystrophy (DMD). Although host immune reactions against the vector as well as transgene products were detected in some instances of the clinical studies, there have been promising observations. Methods of producing AAV vectors for considerable in vivo experimentation and clinical investigations have been developed and a number of studies with AAV vector-mediated muscle transduction were attempted. Notably, an intravenous limb perfusion transduction technique enables extensive transgene expression in the skeletal muscles without noticeable adverse events. Furthermore, cardiac transduction by the rAAV9-microdystrophin would be promising to prevent development of cardiac dysfunction. Recent achievements in transduction technology suggest that long-term transgene expression with therapeutic benefits in DMD treatment would be achieved by the rAAV-mediated transduction strategy with an adequate regimen to regulate host immune response.
- 27 June 2013
- Published by MDPI AG in Pharmaceuticals
- Vol. 6 (7) , 813-836
Open AccessCurrent Challenges and Future Directions in Recombinant AAV-Mediated Gene Therapy of Duchenne Muscular Dystrophy
Various characteristics of adeno-associated virus (AAV)-based vectors with long-term safe expression have made it an exciting transduction tool for clinical gene therapy of Duchenne muscular dystrophy (DMD). Although host immune reactions against the vector as well as transgene products were detected in some instances of the clinical studies, there have been promising observations. Methods of producing AAV vectors for considerable in vivo experimentation and clinical investigations have been developed and a number of studies with AAV vector-mediated muscle transduction were attempted. Notably, an intravenous limb perfusion transduction technique enables extensive transgene expression in the skeletal muscles without noticeable adverse events. Furthermore, cardiac transduction by the rAAV9-microdystrophin would be promising to prevent development of cardiac dysfunction. Recent achievements in transduction technology suggest that long-term transgene expression with therapeutic benefits in DMD treatment would be achieved by the rAAV-mediated transduction strategy with an adequate regimen to regulate host immune response.
- Open Access
- 21 March 2013
- Published by Oxford University Press (OUP) in Human Molecular Genetics
- Vol. 23 (15) , 3990-4000
Dystrophic mdx mice develop severe cardiac and respiratory dysfunction following genetic ablation of the anti-inflammatory cytokine IL-10
Duchenne muscular dystrophy (DMD) is a progressive muscle-wasting disease that causes respiratory and cardiac failure. Inflammation is a key pathological characteristic of dystrophic muscle lesion formation, but its role and regulation in the disease time course has not been sufficiently examined. In the present study, we used IL-10−/−/mdx mice lacking both dystrophin and the anti-inflammatory cytokine, interleukin-10 (IL-10), to investigate whether a predisposition to inflammation affects the severity of DMD with advancing age. The IL-10 deficiency caused a profound DMD phenotype in the dystrophic heart such as muscle degeneration and extensive myofiber loss, but the limb muscle and diaphragm morphology of IL-10−/−/mdx mice was similar to that of mdx mice. Extensive infiltrates of pro-inflammatory M1 macrophages in regeneration of cardiotoxin-injured muscle, altered M1/M2 macrophage phenotype and increased pro-inflammatory cytokines/chemokines production were observed in the diaphragm and heart of IL-10−/−/mdx mice. We characterized the IL-10−/−/mdx mice as a dystrophic model with chronic inflammation and severe cardiorespiratory dysfunction, as evidenced by decreased percent fractional shortening (%FS) and ejection fraction percent (EF%) on echocardiography, reduced lower tidal volume on whole-body plethysmography. This study suggests that a predisposition to inflammation is an important indicator of DMD disease progression. Therefore, the development of anti-inflammatory strategies may help in slowing down the cardiorespiratory dysfunction on DMD.
- 21 March 2013
- Published by Oxford University Press (OUP) in Human Molecular Genetics
- Vol. 23 (15) , 3990-4000
Open AccessDystrophic mdx mice develop severe cardiac and respiratory dysfunction following genetic ablation of the anti-inflammatory cytokine IL-10
Duchenne muscular dystrophy (DMD) is a progressive muscle-wasting disease that causes respiratory and cardiac failure. Inflammation is a key pathological characteristic of dystrophic muscle lesion formation, but its role and regulation in the disease time course has not been sufficiently examined. In the present study, we used IL-10−/−/mdx mice lacking both dystrophin and the anti-inflammatory cytokine, interleukin-10 (IL-10), to investigate whether a predisposition to inflammation affects the severity of DMD with advancing age. The IL-10 deficiency caused a profound DMD phenotype in the dystrophic heart such as muscle degeneration and extensive myofiber loss, but the limb muscle and diaphragm morphology of IL-10−/−/mdx mice was similar to that of mdx mice. Extensive infiltrates of pro-inflammatory M1 macrophages in regeneration of cardiotoxin-injured muscle, altered M1/M2 macrophage phenotype and increased pro-inflammatory cytokines/chemokines production were observed in the diaphragm and heart of IL-10−/−/mdx mice. We characterized the IL-10−/−/mdx mice as a dystrophic model with chronic inflammation and severe cardiorespiratory dysfunction, as evidenced by decreased percent fractional shortening (%FS) and ejection fraction percent (EF%) on echocardiography, reduced lower tidal volume on whole-body plethysmography. This study suggests that a predisposition to inflammation is an important indicator of DMD disease progression. Therefore, the development of anti-inflammatory strategies may help in slowing down the cardiorespiratory dysfunction on DMD.
- Open Access
- 1 January 2013
- Published by Elsevier in Molecular Therapy Nucleic Acids
- Vol. 2 (5) , e95
Robust Long-term Transduction of Common Marmoset Neuromuscular Tissue With rAAV1 and rAAV9
- 1 January 2013
- Published by Elsevier in Molecular Therapy Nucleic Acids
- Vol. 2 (5) , e95
Open AccessRobust Long-term Transduction of Common Marmoset Neuromuscular Tissue With rAAV1 and rAAV9
- Open Access
- 1 January 2012
- Published by Elsevier in Molecular Therapy
- Vol. 20 (1) , 168-177
Long-term Engraftment of Multipotent Mesenchymal Stromal Cells That Differentiate to Form Myogenic Cells in Dogs With Duchenne Muscular Dystrophy
- 1 January 2012
- Published by Elsevier in Molecular Therapy
- Vol. 20 (1) , 168-177
Open AccessLong-term Engraftment of Multipotent Mesenchymal Stromal Cells That Differentiate to Form Myogenic Cells in Dogs With Duchenne Muscular Dystrophy